| Population 2016 |
46 million |
| |
| | | | | |
| Estimates of TB burden*, 2016 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
0.28 |
(0.28–0.29) |
0.61 |
(0.61–0.62) |
| Mortality (HIV+TB only) |
0.053 |
(0.035–0.075) |
0.11 |
(0.07–0.16) |
| Incidence (includes HIV+TB) |
4.7 |
(4–5.5) |
10 |
(8.7–12) |
| Incidence (HIV+TB only) |
0.34 |
(0.29–0.41) |
0.74 |
(0.62–0.88) |
| Incidence (MDR/RR-TB)** |
0.23 |
(0.16–0.3) |
0.5 |
(0.33–0.66) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2016 |
| |
0-14 years |
> 14 years |
Total |
| Females |
0.2 |
(0.17–0.23) |
1.6 |
(1.4–1.9) |
1.8 |
(1.6–2.1) |
| Males |
0.22 |
(0.19–0.25) |
2.7 |
(2.3–3.1) |
2.9 |
(2.4–3.3) |
| Total |
0.42 |
(0.35–0.48) |
4.3 |
(3.7–5) |
4.7 |
(4–5.5) |
| |
| | | | | |
| TB case notifications, 2016 |
|
| Total cases notified |
4 877 |
| Total new and relapse |
4 734 |
| - % tested with rapid diagnostics at time of diagnosis |
20% |
| - % with known HIV status |
|
| - % pulmonary |
72% |
| - % bacteriologically confirmed among pulmonary |
86% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2016 |
100% (87–120) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 |
0.07 (0.06–0.08) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2016 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
|
|
| - on antiretroviral therapy |
|
|
| |
| | | | | |
| Drug-resistant TB care, 2016 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
170
(120–220) |
| Estimated % of TB cases with MDR/RR-TB |
4.2% (2.9–5.8) |
18% (9.4–30) |
|
| % notified tested for rifampicin resistance |
|
|
|
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
|
| Laboratory-confirmed cases |
MDR/RR-TB: , XDR-TB: |
| Patients started on treatment **** |
MDR/RR-TB: , XDR-TB: |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New cases registered in 2015 |
|
|
| Previously treated cases registered in 2015 |
|
|
| HIV-positive TB cases registered in 2015 |
|
|
| MDR/RR-TB cases started on second-line treatment in 2014 |
|
|
| XDR-TB cases started on second-line treatment in 2014 |
|
|
| |
| | | | | |
| TB preventive treatment, 2016 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2017 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed | | |
| | | | | |